Cathay Biotech (SH:688065)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥535,060,039.70, a decrease of 2.51% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was ¥72,027,467.73, down 51.89% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥52,701,901.68, a decline of 61.84% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.13, representing a decrease of 48.00% year-on-year[6]. - Total operating revenue for the first three quarters of 2023 was CNY 1,565,490,018.66, a decrease of 14.8% compared to CNY 1,837,722,247.37 in the same period of 2022[19]. - Net profit for the third quarter of 2023 was CNY 353,343,925.28, down 33.4% from CNY 530,803,141.96 in Q3 2022[20]. - The total profit for the third quarter of 2023 was CNY 392,316,413.35, down 37.1% from CNY 624,095,085.00 in Q3 2022[20]. - Basic earnings per share for Q3 2023 were CNY 0.54, compared to CNY 0.83 in Q3 2022, reflecting a decline of 34.9%[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥18,797,751,335.75, an increase of 5.44% from the end of the previous year[6]. - As of September 30, 2023, the total assets of the company amounted to RMB 18,797,751,335.75, an increase from RMB 17,827,280,594.67 in the previous year[18]. - The company's current assets totaled RMB 8,039,354,753.20, down from RMB 8,475,498,571.63 year-over-year, representing a decrease of approximately 5.17%[16]. - The company's total liabilities increased to RMB 3,531,009,310.20 from RMB 2,789,068,039.70, marking an increase of approximately 26.6%[17]. - The equity attributable to shareholders of the parent company rose to RMB 11,137,776,341.45 from RMB 10,948,955,346.19, indicating an increase of about 1.73%[18]. - The total owner's equity reached RMB 15,266,742,025.55, up from RMB 15,038,212,554.97, indicating a growth of approximately 1.52%[18]. Cash Flow - The company reported a net cash flow from operating activities of ¥530,271,694.96 for the year-to-date, down 18.32% compared to the same period last year[6]. - Cash flow from operating activities for the first three quarters of 2023 was CNY 530,271,694.96, down 18.3% from CNY 649,181,521.54 in the same period of 2022[23]. - The company reported a net cash outflow from investing activities of CNY 1,341,120,412.58, compared to CNY 3,339,639,174.55 in the previous year[23]. - The net cash flow from investing activities was -$1.31 billion, compared to -$3.34 billion in the previous period[24]. - Total cash inflow from financing activities was $507.01 million, down from $1.12 billion year-over-year[24]. - The net cash flow from financing activities was $79.66 million, a decrease from $278.23 million in the prior period[24]. - The net decrease in cash and cash equivalents was -$650.31 million, compared to -$2.29 billion in the previous year[24]. - The ending balance of cash and cash equivalents was $5.57 billion, down from $6.86 billion year-over-year[24]. Research and Development - Research and development expenses for Q3 2023 amounted to ¥40,245,940.08, a decrease of 16.60% year-on-year[6]. - The proportion of R&D expenses to operating revenue was 7.52%, a decrease of 1.27 percentage points compared to the previous year[6]. - Research and development expenses for the first three quarters of 2023 were CNY 126,413,295.65, a decrease of 6.2% compared to CNY 134,754,753.10 in the previous year[19]. Other Financial Metrics - The total non-recurring gains and losses for Q3 2023 amounted to ¥19,325,566.05[7]. - The company experienced a significant decline in net profit due to lower gross margins influenced by international market conditions and decreased exchange gains[9]. - Other income increased significantly to CNY 74,994,852.10 from CNY 24,989,856.97, marking a growth of 200.0%[19]. - The company's inventory decreased to RMB 1,513,748,478.57 from RMB 1,573,637,818.64, a decline of about 3.81%[16]. - The total non-current assets increased to RMB 10,758,396,582.55 from RMB 9,351,782,023.04, reflecting an increase of approximately 15.04%[16]. - The company's retained earnings increased to RMB 2,016,348,401.59 from RMB 1,807,249,349.68, showing an increase of about 11.6%[17]. - Short-term borrowings surged to RMB 521,144,748.54 from RMB 161,469,940.15, representing an increase of approximately 223.5%[16].